Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor
Some researchers believe that upregulation of PD-L1 allows cancers to evade the host immune system. This research has encouraged development of PD-L1 inhibitor cancer therapies, some that are currently
"We are very excited to have a physician and personalized medicine expert as accomplished as
"The ability to qualify patients for targeted therapy in the absence of biopsy tissue, through a simple blood test, is a provocative concept,"
About
About
Dr.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to
CONTACT: Investor Contact:Source:The Ruth Group David Burke Tel: 646-536-7009 dburke@theruthgroup.com
News Provided by Acquire Media